aTyr Pharma, Inc.

aTyr Pharma, Inc.

5.24
USD
-0.86
(-14.17%)
-21.74EPS
30.44MMarket Cap
Mar 18Next Earn

Total Valuation

USD

As of September 30, 2026, aTyr Pharma, Inc. carries a market capitalization of 30.44M, placing it among publicly traded companies globally. Its enterprise value stands at -7.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap30.44M
Enterprise Value-7.58M

Important Dates

aTyr Pharma, Inc.'s next confirmed earnings release is scheduled for March 18, 2027.

Earnings Date3/18/2027

Share Statistics

As of September 30, 2026, aTyr Pharma, Inc. has 2.51M shares outstanding.

Shares Outstanding2.51M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio0.90
P/TBV Ratio0.90
P/FCF Ratio-0.68
P/OCF Ratio-0.68

Financial Position

As of September 30, 2026, aTyr Pharma, Inc. maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

Current Ratio3.05
Quick Ratio3.00
Debt / Equity32.31
Debt / EBITDA-0.20

Financial Efficiency

Over the twelve months ended September 30, 2026, aTyr Pharma, Inc. posted a negative return on equity (ROE) of -93.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.07, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-93.37
Return on Assets (ROA)-64.07
Employee Count58.00

Stock Price Statistics

USD

As of the close on November 16, 2026, aTyr Pharma, Inc.'s stock has declined approximately 82.61% over the past 52 weeks. The 50-day moving average sits at 10.03, while the 200-day moving average is 22.92.

52-Week Price Change-82.61%
50-Day Moving Average10.03
200-Day Moving Average22.92

Income Statement

USD

Over the twelve months ended September 30, 2026, aTyr Pharma, Inc. generated - - in revenue and converted that into -53.32M in net income, yielding earnings per share of -21.74. EBITDA reached -54.31M, while operating income came in at -55.90M.

Operating Income-55.90M
Pretax Income-53.32M
Net Income-53.32M
EBITDA-54.31M
EBIT-55.90M
Earnings Per Share (EPS)-21.74

Balance Sheet

USD

As of September 30, 2026, aTyr Pharma, Inc. holds 48.75M in cash and equivalents against 10.92M in total debt, resulting in a net debt position of -13.14M. Total book value stands at 33.98M, with working capital of 33.69M providing operational flexibility.

Cash & Cash Equivalents48.75M
Total Debt10.92M
Net Debt-13.14M
Equity (Book Value)33.98M
Book Value Per Share13.53
Working Capital33.69M

Cash Flow

USD

aTyr Pharma, Inc. produced -43.57M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -287,000.00 in capital expenditures, free cash flow totaled -43.86M - equivalent to -17.89 per share.

Operating Cash Flow-43.57M
Capital Expenditures-287,000.00
Free Cash Flow-43.86M
FCF Per Share-17.89

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -147.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.22, meaning aTyr Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-1.22
FCF Yield-147.57

Stock Splits

aTyr Pharma, Inc.'s most recent stock split took place on October 29, 2026 with a 40:1 split ratio.

Last Split Date10/29/2026
Split Ratio40:1

Scores

As of September 30, 2026, aTyr Pharma, Inc. has an Altman Z-Score of -16.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-16.82